Damora Therapeutics (DMRA) Payables (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly Payables came in at $819000.0 in Q1 2026, up 131.36% YoY from $354000.0 in Q1 2025, and up 84.46% on a QoQ basis from $444000.0 in Q4 2025.
Damora Therapeutics (DMRA) Payables (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 8 years of Payables data on file, last reported at $819000.0 in Q1 2026.
- Quarterly Payables rose 131.36% year-over-year to $819000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $819000.0 (up 131.36% YoY) and the FY2025 annual result came in at $444000.0, up 17.77% from the prior year.
- Payables advanced to $819000.0 in Q1 2026, from $444000.0 in the prior quarter.
- In the past five years, Payables ranged from a high of $5.6 million in Q2 2023 to a low of $354000.0 in Q1 2025.
- A 5-year average of $1.9 million and a median of $1.7 million in 2024 frame the typical range for Payables.
- Annual changes were most pronounced in 2023 — Payables jumped 134.77% — and 2024, when it plunged 88.76%.
- Tracing DMRA's Payables over 5 years: stood at $3.4 million in 2022, then sank by 49.19% to $1.7 million in 2023, then slumped by 77.85% to $377000.0 in 2024, then grew by 17.77% to $444000.0 in 2025, then soared by 84.46% to $819000.0 in 2026.
- The last three Payables figures came in at $819000.0 (Q1 2026), $444000.0 (Q4 2025), and $520000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | 3.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.48 Mn |
| Mar 31, 2026 | 819,000.00 |
| Dec 31, 2025 | 444,000.00 |
| Sep 30, 2025 | 520,000.00 |
| Jun 30, 2025 | 756,000.00 |
| Mar 31, 2025 | 354,000.00 |
| Dec 31, 2024 | 377,000.00 |
| Sep 30, 2024 | 503,000.00 |
| Jun 30, 2024 | 724,000.00 |
| Mar 31, 2024 | 1.67 Mn |
| Dec 31, 2023 | 1.70 Mn |
| Sep 30, 2023 | 4.48 Mn |
| Jun 30, 2023 | 5.56 Mn |
| Mar 31, 2023 | 3.55 Mn |
| Dec 31, 2022 | 3.35 Mn |
| Sep 30, 2022 | 1.91 Mn |
| Jun 30, 2022 | 2.82 Mn |
| Mar 31, 2022 | 3.22 Mn |
| Dec 31, 2021 | 1.53 Mn |
| Sep 30, 2021 | 1.98 Mn |